These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 11904959)
1. [Rationale for Herceptin in the clinical use]. Ebi H; Sasaki Y Nihon Rinsho; 2002 Mar; 60(3):463-7. PubMed ID: 11904959 [TBL] [Abstract][Full Text] [Related]
2. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer]. Dank M Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175 [TBL] [Abstract][Full Text] [Related]
3. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Goldenberg MM Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534 [TBL] [Abstract][Full Text] [Related]
4. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Shak S Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196 [TBL] [Abstract][Full Text] [Related]
5. Progression and treatment of HER2-positive breast cancer. Davoli A; Hocevar BA; Brown TL Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Jahanzeb M Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259 [TBL] [Abstract][Full Text] [Related]
7. Antibodies as molecular target-based therapy: trastuzumab. Tokuda Y Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577 [TBL] [Abstract][Full Text] [Related]
8. Current and planned clinical trials with trastuzumab (Herceptin). Baselga J Semin Oncol; 2000 Oct; 27(5 Suppl 9):27-32. PubMed ID: 11049054 [TBL] [Abstract][Full Text] [Related]
9. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?]. Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? Castrellon AB; Glück S Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789 [TBL] [Abstract][Full Text] [Related]
12. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Leonard DS; Hill AD; Kelly L; Dijkstra B; McDermott E; O'Higgins NJ Br J Surg; 2002 Mar; 89(3):262-71. PubMed ID: 11872048 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Baselga J; Perez EA; Pienkowski T; Bell R Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734 [TBL] [Abstract][Full Text] [Related]
15. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Emens LA Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197 [TBL] [Abstract][Full Text] [Related]